Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is based in Burlingame, California.